Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic ASCs for Primary Graft Dysfunction in Lung Transplantation
NCT04714801Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Oct 2020
- Primary completion
- Nov 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adipose derived mesenchymal stromal cells in primary graft dysfunction (PGD) (3 arms), sponsored by Rigshospitalet. Primary endpoint: Pulmonary graft dysfunction (PDG) at 3 days. Status: unknown.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
primary graft dysfunction (PGD)
Beyond the preview
Go deeper on NCT04714801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714801.